PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMENT OF ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMENT OF ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
Inclusion Criteria:
Exclusion Criteria:
Bakersfield, California 93309, United States
Redondo Beach, California 90277, United States
Santa Monica, California 90404, United States
Lawrenceville, Georgia 30046, United States
Snellville, Georgia 30078, United States
Halle, 06120, Germany
Mainz, 55101, Germany
MĂĽnchen, 81675, Germany
Meldola, FC 47014, Italy
Rimini, 47900, Italy
Samara, 443031, Russia
Ufa, 450054, Russia
Dnipropetrovsk, 49102, Ukraine
Donetsk, 83087, Ukraine
Donetsk, 83092, Ukraine